Welcome to our dedicated page for TREVENA news (Ticker: TRVN), a resource for investors and traders seeking the latest updates and insights on TREVENA stock.
Trevena, Inc. (Nasdaq: TRVN) is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies targeting G protein-coupled receptors (GPCRs). The company's mission is to improve patient outcomes and reduce healthcare costs through novel therapies. Trevena's pipeline includes four key drug candidates:
- TRV130 (OLINVYK®): An FDA-designated breakthrough therapy for the intravenous treatment of acute moderate to severe pain, currently in Phase 3 testing. Recently, OLINVYK's effectiveness was assessed in the VOLITION study, showing promising results in terms of respiratory, gastrointestinal, and cognitive function outcomes in postoperative settings.
- TRV027: Evaluated in a Phase 2b study for treating acute heart failure, this candidate aims to address unmet needs in cardiovascular treatment.
- TRV734: Completed Phase 1 testing for the oral treatment of acute and chronic pain, TRV734 seeks to provide a non-opioid alternative for pain management.
- TRV250: In preclinical development for migraine treatment, focusing on innovative solutions for CNS disorders.
Trevena's pipeline is based on Nobel Prize-winning research, emphasizing its commitment to pioneering medical advancements. The company has collaborations with prominent institutions like Wake Forest Baptist Health and the Cleveland Clinic, ensuring rigorous evaluation and development of its therapies. Trevena is also exploring TRV045 for diabetic neuropathic pain and epilepsy, showcasing the potential impact beyond pain management.
Financially, Trevena has shown resilience, recently reporting a net loss reduction and strengthening its balance sheet with significant capital injections. The company continues to focus on strategic partnerships and innovative research to maintain its competitive edge in the biopharmaceutical industry.
For more information, please visit www.Trevena.com.
Trevena, Inc. (Nasdaq: TRVN) announced that its drug OLINVYK (oliceridine) has been classified as a Schedule II controlled substance by the DEA, allowing distribution starting in November. This approval marks a significant milestone for the company, as it aims to provide an alternative to IV morphine for acute pain management. With approximately 45 million patients treated annually, OLINVYK offers rapid onset and requires no dosage adjustments for renal-impaired patients. The company reported cash reserves of $112.7 million, sufficient to fund operations through 2022.
Trevena, Inc. (Nasdaq: TRVN) announced three presentations at ANESTHESIOLOGY® 2020, showcasing new analyses from the Phase 3 program of OLINVYK (oliceridine) injection. Key findings revealed significant improvements in respiratory safety and gastrointestinal tolerability compared to IV morphine. OLINVYK demonstrated a lower incidence of respiratory safety events (12.8%-13.8%) versus morphine (22.8%-23.4%). Additionally, it showed better performance regarding nausea and vomiting rates, establishing its potential as a safer alternative for managing acute pain.
Trevena, Inc. (Nasdaq: TRVN) announced three presentations at the 2020 American College of Clinical Pharmacology Annual Meeting from September 21-23, discussing TRV027 as a potential COVID-19 treatment, along with OLINVYK and TRV250 data. A live presentation on TRV027 highlighted its targeted action for ARDS and clotting issues in COVID-19 patients. OLINVYK’s benefit-risk profile compared to morphine was presented, showing improved safety. TRV250's Phase 1 study indicated it’s well-tolerated for migraine treatment.
Trevena, Inc. (Nasdaq: TRVN) announced its participation in three upcoming conferences in September 2020. The events include the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, the Cantor Fitzgerald Virtual Global Healthcare Conference on September 17, and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 23. Key presentations will be led by senior executives including Carrie Bourdow and Bob Yoder. Investors can access the webcasts on the Company's website for further insights into Trevena's focus on CNS disorders and its product pipeline.
Trevena, Inc. (Nasdaq: TRVN) announced key publications on the respiratory safety of OLINVYK (oliceridine), demonstrating its improved profile over IV morphine. A clinical utility function analysis revealed OLINVYK offers a higher probability of analgesia with lower respiratory depression risks. In Phase 3 studies, patients receiving OLINVYK experienced fewer dosing interruptions due to respiratory safety events compared to those receiving morphine. Approved by the FDA in August 2020, OLINVYK is intended for acute pain management in adults.
Trevena, Inc. has announced the initiation of a proof-of-concept study for TRV027, a selective AT1 receptor agonist aimed at treating acute lung damage and abnormal blood clotting in COVID-19 patients. Sponsored by Imperial College London, the randomized study will enroll approximately 60 hospitalized patients, focusing on TRV027's effectiveness in reducing clotting and improving lung function. Topline data is expected in Q1 2021. TRV027 has shown prior efficacy in nonclinical studies and a low dropout rate in previous trials.
Trevena, Inc. (Nasdaq: TRVN) announced a $3 million milestone payment from its Chinese partner Nhwa following the U.S. approval of OLINVYK™ (oliceridine) injection. This payment is part of a licensing agreement where Nhwa is tasked with developing and commercializing OLINVYK in China. The company anticipates further milestone payments and a 10% royalty on net sales in the region. OLINVYK is indicated for adults requiring intravenous opioid analgesics for severe pain, though it awaits scheduling by the DEA before distribution.
On August 14, 2020, Trevena, Inc. (TRVN) announced that CEO Carrie Bourdow will participate in a fireside chat during the JMP Securities CNS Forum, scheduled for August 19-20, 2020. The chat will take place on August 20 at 12:30 p.m. Eastern Time. The discussion will focus on the company's ongoing development of novel CNS treatments, including its approved product OLINVYK™ and innovative candidates like TRV250 for migraine and TRV734 for opioid use disorder. For further details, the webcast link is provided in the press release.
Trevena, Inc. (Nasdaq: TRVN) has priced a public offering of 21,739,131 shares of its common stock at $2.30 per share, aiming to raise around $50 million before deductions. The underwriters have a 30-day option to purchase an additional 3,260,869 shares. Proceeds will primarily fund the commercialization of OLINVYK and support clinical development for pipeline assets. The offering is expected to close around August 14, 2020. Guggenheim Securities is the lead manager for this offering.
Trevena, Inc. (Nasdaq: TRVN) announced an underwritten public offering of its common stock, aiming to raise funds for its CNS disorder treatments. The offering includes a 30-day option for underwriters to purchase an additional 15% of the shares. Lead managers are Guggenheim Securities and Cantor Fitzgerald. The offering is subject to market conditions, with no guarantee on its completion or terms. Trevena has one approved product, OLINVYK™, and is developing several investigational drug candidates.
FAQ
What is the current stock price of TREVENA (TRVN)?
What is the market cap of TREVENA (TRVN)?
What is Trevena, Inc.?
What is OLINVYK®?
What recent developments has Trevena announced?
What is TRV045?
How is Trevena's financial performance?
What types of products does Trevena develop?
Are Trevena's products FDA approved?
What partnerships does Trevena have?
Where can I find more information about Trevena’s research?
What are the primary focus areas of Trevena's research?
